钠碘转运体基因介导的肿瘤放射性核素治疗研究

张俊; 刘增礼

张俊 , 刘增礼

文章导航 > 国际放射医学核医学杂志 > 2008, 32 > 1: (8-11)

引用本文:

Citation:

钠碘转运体基因介导的肿瘤放射性核素治疗研究

张俊¹,
刘增礼^2, ,

1. 225300 江苏, 江苏省泰州市人民医院核医学科;
2. 215004 苏州, 苏州大学附属第二医院核医学科

通讯作者: 刘增礼, liuzengli@126.com

中图分类号: R817.5;R730.5

Sodium iodide symporter gene-mediated radionuclide therapy of tumors

ZHA NG Jun¹,
LIU Zeng-li^2, ,

1. Department of Nuclear Medicine, Taizhou People's Hospital, Taizhou 225300, China;
2. Department of Nuclear Medicine, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China

Corresponding author: LIU Zeng-li, liuzengli@126.com

CLC number: R817.5;R730.5

摘要: 钠碘转运体(NKS)是一种跨膜糖蛋白,介导碘的主动摄取,使得放射性碘用于治疗不摄碘的肿瘤成为可能。目前NIS基因已被成功转入多种肿瘤并表达出有功能的NIS蛋白,但治疗的效果并不令人满意。为此,研究者们应用不同的方法进行了改进,并收到较好的效果。
- 基因疗法 /
- 碘放射性同位素 /
- 肿瘤 /
- 钠碘转运体
Abstract: The sodium iodide symporter (NIS) is a transmembrane glycoprotein responsible for uptake of iodide into cells. It has raised the possibility of using radio-iodine for treatment of those tumors that cannot accumulate iodide. The NIS gene has been transferred into a variety of tumors and induced NIS functional expression successfully. However, the effect of therapy is disappointing. Hence, many investigators apply several different approaches to their studies and obtain more effective results.
- Gene therapy /
- Iodineradioisotopes /
- Neoplasms /
- Sodium iodide svmporter
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	De La Vieja A, Dohan O, Levy O, et al. Molecular analysis of the sodium/iodide symporter:impact on thyroid and extrathyroid pathophysiology[J]. Physiol Rev, 2000, 80(3):1083-1105.
[2]	Spitzweg C, Joba W, Eisenmenger W, et al. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa[J]. J Clin Endocrinol Metab, 1998, 83(5):1746-1751.
[3]	Huang M, Batra RK, Kogai T, et al. Ectopie expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer[J]. Cancer Gene Ther, 2001, 8(8):612-618.
[4]	Boland A, Magnon C, Filetti S, et al. Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers[J]. Thyroid, 2002, 12(1):19-26.
[5]	Wenzel A, Upadhyay G, Schmitt TL, et al. Iodination of proteins in TPO transfected thyroid cancer cells is independent of NIS[J]. Mol Cell Endocrinol, 2003, 213(1):99-108.
[6]	Spitzweg C, Zhang S, Bergert ER, et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res, 1999, 59(9):2136-2141.
[7]	Spitzweg C, O'Connor MK, Bergert ER, et al. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter[J]. Cancer Res, 2000, 60(22):6526-6530.
[8]	Kakinuma H, Bergert ER, Spitzweg C, et al. Probasin promoter (ARR (2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer[J]. Cancer Res, 2003, 63(22):7840-7844.
[9]	Dwyer RM, Bergen ER, O'Connor MK, et al. In vivo radioiodide imaging and treatment of breast cancer xenografis after MUC1-driven expression of the sodium iodide symporter[J]. Clin Cancer Res, 2005, 11(4):1483-1489.
[10]	Dwyer RM, Bergert ER, O'Connor MK, et al. Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice[J]. Gene Ther, 2006, 13(1):60-66.
[11]	Sieger S, Jiang S, Schonsiegel F, et al. Tumour-specific activation of the sodium/iodide symporter gene under control of the glucose transporter gene 1 promoter (GTI-1.3)[J]. Eur J Nucl Med Mol Imaging, 2003, 30(5):748-756.
[12]	Dingli D, Diaz RM, Bergert ER, et al. Genetically targeted radiotherapy for multiple myeloma[J]. Blood, 2003, 102(2):489-496.
[13]	Schipper ML, Weber A, Behe M, et al. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells[J]. Cancer Res, 2003, 63(6):1333-1338.
[14]	Scholz IV, Cengic N, Baker CH, et al. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer[J]. Gene Ther, 2005, 12(3):272-280.
[15]	Cengic N, Baker CH, Schǚtz M, et al. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression[J]. J Clin Endocrinol Metab, 2005, 90(8):4457-4464.
[16]	Schmutzler C, Winzer R, Meissner-Weigl J, et al. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells[J]. Biochem Biophys Res Commun, 1997, 240(3):832-838.
[17]	Kogai T, Schahz JJ, Johnson LS, et al. Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line[J]. Proe Natl Acad Sci USA, 2000, 97(15):8519-8524.
[18]	Kogai T, Kanamoto Y, Che LH, et al. Systemic retinoic acid treatment induces sodium/iodide symporter expression and radioiodide uptake in mouse breast cancer models[J]. Cancer Res, 2004, 64(1):415-422.
[19]	Spitzweg C, Scholz IV, Bergert ER, et al. Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells[J]. Endocrinology, 2003, 144(8):3423-3432.
[20]	Unterholzner S, Willhauck MJ, Cengic N, et al. Dexamethasone stimulation of retinoic Acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells[J]. J Clin Endocrinol Metab, 2006, 91(1):69-78.
[21]	Dadachova E, Bouzahzah B, Zuckier LS, et al. Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS)[J]. Nucl Med Biol, 2002, 29(1):13-18.
[22]	Carlin S, Akabani G, Zalutsky MR. In vitro eytotoxieity of (211)atastatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter[J]. J Nucl Med,2003,44(11):1827-1838.
[23]	Dwyer RM, Schatz SM, Bergert ER, et al. A preclinieal large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer[J]. Mol Ther, 2005, 12(5):835-841.

[1]	郭睿 , 李彪 . 钠碘同向转运体基因介导放射性碘治疗肿瘤的研究进展. 国际放射医学核医学杂志, 2010, 34(3): 147-151. doi: 10.3760/cma.j.issn.1673-4114.2010.03.005
[2]	翟红彦 , 苏成海 . 基因治疗联合放射治疗恶性肿瘤的分子机制. 国际放射医学核医学杂志, 2009, 33(2): 113-116. doi: 10.3760/cma.j.issn.1673-4114.2009.02.015
[3]	赵艳芝 , 李进 , 王芹 , 穆传杰 . 恶性肿瘤基因治疗和放射治疗相互作用的机制及联合治疗展望. 国际放射医学核医学杂志, 2006, 30(4): 250-253.
[4]	张耀文 , 曹永珍 , 李进 , 王芹 . 基因治疗联合放射治疗恶性肿瘤. 国际放射医学核医学杂志, 2008, 32(4): 247-250.
[5]	田玥 , 苏成海 . 恶性肿瘤的放射治疗联合基因治疗研究进展. 国际放射医学核医学杂志, 2008, 32(1): 43-46.
[6]	秦洋洋 , 付巍 . 分化型甲状腺癌患者¹³¹I治疗后唾液腺功能变化的诊疗进展. 国际放射医学核医学杂志, 2022, 46(7): 419-424. doi: 10.3760/cma.j.cn121381-202102025-00136
[7]	郑薇 , 谭建 . 甲状腺癌的基因治疗. 国际放射医学核医学杂志, 2007, 31(4): 197-201.
[8]	王芹 , 刘晓秋 , 李进 , 荣庆林 , 宋力 , 刘强 , 张恒 , 樊飞跃 . 白细胞介素21基因联合不同剂量γ射线照射对乳腺癌细胞生长的影响. 国际放射医学核医学杂志, 2012, 36(2): 94-96. doi: 10.3760/cma.j.issn.1673-4114.2012.02.009
[9]	于雷 , 陈红红 , 程文英 , 邵春林 . 放射性籽源薄层片植入治疗肿瘤的研究进展. 国际放射医学核医学杂志, 2006, 30(6): 369-372.
[10]	李玮 , 谭建 . 肿瘤基因治疗相关的特异性启动子研究新进展. 国际放射医学核医学杂志, 2014, 38(3): 185-189. doi: 10.3760/cma.j.issn.1673-4114.2014.03.011